GRCL (Gracell Biotechnologies Ltd) Likuiditas cepet

Gracell Biotechnologies (GRCL) is protected by exclusive patents for accelerated CAR-T cell production in the US and China, operating within the strict regulatory frameworks of the FDA and NMPA. The company is implementing FasTCAR technology to reduce leukemia drug manufacturing timelines from several weeks to just a few days. Serving as the primary valuation tool, this chart on GURU.Markets reflects the price action of an asset whose scalability is limited by the resources of its parent structure, with the current metric standing at 7.78.

This indicator assesses a company's ability to immediately settle short-term obligations without liquidating inventory. The quick ratio visualizes the volume of available capital by excluding low-liquidity assets. The calculation is based on the ratio of cash and accounts receivable to current liabilities. For Gracell Biotechnologies, a leader in CAR-T therapy, such solvency is critical when financing costly cell research prior to its integration into the AstraZeneca structure.